A new weight loss drug could beat Ozempic's side effect problem
The Denmark-based drug maker Zealand Pharma said Tuesday that its experimental weight-loss drug could help patients lose ...
FiercePharma9h
Madrigal’s Rezdiffra has launched a new MASH market, but ‘tremendous change’ is on the horizon
With the FDA approval of the first specific drug for Metabolic Associated Steatohepatitis (MASH) in March this year, Madrigal’s Rezdiffra is a pioneer in a market set for rapid change. | With the FDA ...
Outsourcing-pharma11h
Novo Nordisk’s semaglutide shows additional cardiovascular benefits in overweight patients
Clinical trial results have revealed that semaglutide treatment significantly reduced hospital admissions in overweight and ...
Pharmabiz13h
Novo Nordisk announces positive results from phase 3 ESSENCE trial of semaglutide 2.4 mg to treat adults with MASH and liver fibrosis
Part 1 of the ESSENCE trial evaluated the effect of once-weekly semaglutide 2.4 mg on liver tissue (histology) compared to placebo on top of standard of care for the first 800 randomised people at 72 ...
Daily14h
Semaglutide 2.4 mg may significantly improve liver fibrosis and resolve MASH in ESSENCE trial
According to Headline results from part 1 of the phase 3 ESSENCE trial, Semaglutide 2.4 mg may significantly improve liver ...
Ozempic Gives Strong Relief to Severe Knee Pain, Clinical Trial Suggests
The drug semaglutide is already proving incredibly effective in tackling diabetes (under the brand name Ozempic) and weight loss (as Wegovy), and a new study suggests it can do wonders for a type of ...